Lisata Therapeutics (NASDAQ:LSTA) Issues Quarterly Earnings Results

Lisata Therapeutics (NASDAQ:LSTA) released its quarterly earnings data on Friday. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.39, FiscalAI reports.

Lisata Therapeutics Stock Performance

LSTA traded down $0.07 during trading on Friday, hitting $1.21. 104,864 shares of the stock were exchanged, compared to its average volume of 118,206. The firm has a 50 day simple moving average of $1.28 and a 200 day simple moving average of $2.88. The firm has a market cap of $13.07 million, a price-to-earnings ratio of -0.74 and a beta of 1.04. Lisata Therapeutics has a 1 year low of $0.96 and a 1 year high of $5.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cancer and other serious diseases. The company’s research focuses on improving the delivery of treatments to solid tumors. Its lead investigational product, certepetide (also known as LSTA1 or CEND-1), is a peptide being studied in combination with existing cancer therapies. Clinical development has included pancreatic cancer and other solid tumors; certepetide is not an approved commercial treatment. Lisata adopted its current name in 2022 following a merger involving Cend Therapeutics and the former Caladrius Biosciences.